June 2019 Missouri Registry and Research Center Ed 19:02 Breast Show-Me-Tips

Coding...Abstracting...Education… Coding Systemic Therapy

Breast Cancer Systemic Therapy

Chemotherapy Subcategory

Abraxane (Protein-bound )

Afinitor () Cytostatic agent-antiangiogenesis agent and mTOR inhibitor

Capecitabine (Xeloda)

Carboplatin (Paraplatin) Alkylating agent, Platinum analog

Cyclophosphamide (Cytoxan, Clafen) Alkylating agent

Docetaxel (Taxotere) Taxane

Doxorubicin (Adriamycin) Antitumor antibiotic

Epirubicin ( Hydrochloride, Ellence) , Antitumor antibiotic

Epothilone (, Ixempra) Antimitotic agent

Eribulin ( mesylate, Halaven) Inhibitor of microtubular dynamics

Fluorouracil (5-FU) Antimetabolite (Gemzar, Gemcitabine Hydrochloride) Antimetabolite

Lapatinib Ditosylate (Tykerb) Tyrosine inhibitor

Methotrexate (Folex, Folex PFS, Mexate, Mexate AQ) Antimetabolite

Paclitaxel (Taxol) Mitotic inhibitor, plant , Taxane

Palbociclib (Ibrance) CDK inhibitor

Thiotepa (Thioplex) Alkylating agent

Vinblastine (Velban, Velsar, Sulfate) Plant alkaloid

Adapted from the presentation “Coding Systemic Treatment” and used with permission of Mary B. Davidson, RN, BSN, MN, CTR Source: “Coding Systemic Treatment” presented at the 2018 NCRA conference by Mary B. Davidson, RN, BSN, MN, CTR

This project was supported in part by a cooperative agreement between the Centers for Disease Control and Prevention (CDC) and the Missouri Department of Health and Senior Services (DHSS) (NU58DP006299-02) and a Surveillance Contract between DHSS and the University of Missouri. 1

June 2019 Missouri Cancer Registry and Research Center Ed 19:02 Breast Show-Me-Tips

Coding...Abstracting...Education… Coding Systemic Therapy Systemic Therapy

Hormone Therapy Subcategory Anastrozole (Arimidex) Exemestane (Aromasin) Aromatase inhibitor (Faslodex) SERD Goserelin Acetate (Zoladex) Gonadotropin-releasing hormone (Femara) Nonsteroidal aromatase inhibitor Megesterol Acetate (Megace) Progestin Tamoxifen (Nolvadex, Tamoxifen Citrate) Nonsteroidal antiestrogen

Biological Response Modifiers Subcategory

Ado- emtansine (Kadcyla) Antibody-drug conjugate (Perjeta) Cytostatic agent—tyrosine kinase inhibitor Humanized monoclonal antibody

Trastuzumab (Herceptin) —epidermal growth factor receptor

Common Regimens Biophosphates (NOT CODED) AC: Adriamycin & Cytoxan (Ancillary Agents given for Bone Mets) AC-T: Adriamycin, Cytoxan then Taxol CAF: Cytoxan, Adriamycin & 5-FU Denosumab (Xgeva) coded if given to treat Giant CMF: Cytoxan, & 5-FU Cell Tumors of the Bone FEC: 5-FU, Epirubicin & Cytoxan Pamidronate Disodium (Aredia) TAC: Taxotere, Adriamycin & Cytoxan Zoledronic acid (Zometa) TCH: Taxotere, & Herceptin TC: Taxotere & Cytoxan

Adapted from the presentation “Coding Systemic Treatment” and used with permission of Mary B. Davidson, RN, BSN, MN, CTR Source: “Coding Systemic Treatment” presented at the 2018 NCRA conference by Mary B. Davidson, RN, BSN, MN, CTR

This project was supported in part by a cooperative agreement between the Centers for Disease Control and Prevention (CDC) and the Missouri Department of Health and Senior Services (DHSS) (NU58DP006299-02) and a Surveillance Contract between DHSS and the University of Missouri. 2